Watmind USA sells its products globally for a wide variety of healthcare applications. Due to the global coronavirus COVID19 pandemic, we are currently selling our products and systems for purposes of coronavirus SARS-CoV-2 Detection, Surveillance and Infection Deterrence. We sell our portable analyzers to Factories, Schools, Casinos, Cruise Lines, Amusement Parks, Sports and Music Venues, Governmental Agencies, Petrochemical Companies, Emergency Medical Services, Professional Sports and any organization or facility that needs to stay open safely without interruption. Our portable and easy to use systems detects the coronavirus in the blood (Nucleocapsid antigenemia) prior to the subject becoming contagious by droplets, therefore, preventing on-site viral exposures or outbreaks which shut down your school or facility. Plus it performs many more functions such as tracking viral immunity (antibody formation against coronavirus SARS-CoV-2 S1 Subunit) and other critical health screening markers used in medical care. See actual system data below to see the power and versatility. If new viral variants are resistant to the vaccine given to a subject we would expect to see the mutated coronavirus in the blood after contagious exposure on our system. This gives the system full spectrum monitoring control and complements laboratory based molecular systems by providing rapid point of need data. For Surveillance and Research Use Only. Not for use in diagnostic procedures.
Whole blood test results from our Disposable Test Kit (DTK) Lateral Flow Assays
Watmind Ranks Number One (#1) for COVID19 Rapid Antigen Test Performance
(Ranked 1st out of 32 commercially available test systems)
Rapid comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests
Center for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany.
Department of Infectious Diseases, Division of Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
DKFZ-ZMBH Alliance, Heidelberg, Germany.
Denzler et.al “Among the 32 investigated AgPOCTs, we identified four reliably well performing AgPOCTs, which detected the Ct28 sample (~1.7*10⁵ copies/ ml) as SARS-CoV-2 positive in all replicates (Group I). Watmind “represents the test winner in our study and is also among the best three AgPOCTs out of 122 tested products with a sensitivity of 82 % in samples with Ct values ranging from 17 to 35 corresponding to viral loads of >10⁸ to 10³ SARS-CoV-2 genome copies per ml (Scheiblauer et al., 2021).”
Our portable rapid M2/M5 chemiluminescent microfluidic immunoassay analyzers allows you to fully protect your facility and organization in the point of need in a mobile environment by providing real-time readout in 13-15 minutes on a subject’s exact coronavirus active exposure history (Nucleocapsid SARS-CoV-2 antigenemia) and Vaccination status (S1 Antibody Titers), days prior to the subject becoming contagious by respiratory or aerosolized droplets.
Other available systems (Molecular/Nucleic Acid Amplification Systems and Rapid Antigen Immunofluorescent Assays) detect the coronavirus AFTER IT IS ALREADY CONTAGIOUS BY AEROSILIZED RESPIRATORY DROPLETS which is too late for purposes of infective exposure prevention.
The Watmind USA system by detecting the coronavirus SARS-CoV-2 virus during its incubation in the blood (N-Antigenemia) after successful exposure transmission from respiratory spreader to new viral host, gives you the critical time (days to weeks depending on variant) needed to respond appropriately. Because of the advance warning, users are able to deploy efficient, practical, and cost-effective once a week testing protocols. This dramatically reduces per test cost (5X reduction) and per employee/subject monitoring costs (10-100x reduction).
The Watmind USA system prevent site entry (on-site exposures) of asymptomatic coronavirus incubators (i.e. coronavirus super spreaders) which represent more than half of the case spread. Therefore, the system prevents on-site coronavirus contamination and exposure by respiratory droplets and the resulting on-site outbreaks which result in costly shut-down and site remediation interventions such as clean-ups and contract tracing post outbreak.
The system detects the coronavirus Nucleocapsid Antigen in the blood (N-antigenemia) by fast pinprick or blood draw before subject is contagious by respiratory aerosol droplets in the workplace, school, or facility. This system accurately determine exposed contacts by pinprick blood testing, thus removing the guess work around contact trace investigations or the use of location applications. The portable analyzers also have Bio-Chips to determine immunity status post-infection or post-vaccine. This eliminates the guess work in Vaccination Tracking as the system tells you the antibody titer of the subject. This eliminates false immunization reporting, unknown waning immunity and immunocompromised poor vaccine responder health risks, and can be co-tested with Ag chip to tell you real time variant vaccine breakthroughs in 15 minutes. The Microfluidic Coronavirus Reagent Chips also can process samples such as oral swabs, sputum, and saliva to detect the viral antigen in the upper airway.
This versatility and multi-niche capability is critical (all other systems in use have failed in surveillance settings) for essential workforce environments such as Armed Services, First Responders, Government Agencies, Ports and Shipping, Energy, Power, Engineering, IT, Healthcare, Public Health, Water, Transportation, Telecommunications, Banks, Factories, Nursing Homes and others.
This easy to use system, low test burden, and low per subject cost means the system is also perfect for non-essential workforce environments such as Schools, Recreational Facilities, Sports Organizations, Stadiums, Entertainment Venues, Casinos, Hotels, Resorts, Hospitality, Retail, Shopping Malls, Private Clubs, Marinas, Cruise Ships, Spas, and all other establishments or organizations who desire to stay open safely with practical testing protocols without the costly shut-downs. Call us to here about our on-going success stories during the pandemic for this state-of-the art technology which is brand new to the USA market. Please see actual coronavirus (SARS-CoV-2) COVID19 surveillance data below from our system. This is the ultimate coronavirus detection platform.
Routine Watmind Coronavirus surveillance gives you pre-warning of respiratory infection, allowing targeted measures to be taken to stop the virus before it enters your facility.
Accurate test results in less than 15 minutes
BIO-CHIPS REQUIRE NO REAGENTS
TEST KITS OR BIO-CHIPS FOR TOTAL ANTIBODIES, IgM, IgG, or Viral Antigen
QUALITATIVE and SEMI-QUANTITATIVE BIO-CHIPS
Fingertip blood sample can minimize infection risk
Real-time & on-site spot test, no need for laboratory conditions
According to coronavirus global clinical experience, there is a high rate of false negatives and/or false positives using nucleic acid RT-PCR tests and Rapid Antigen Tests in the point of care setting. These deficiencies have resulting in failure to achieve effective COVID19 coronavirus monitoring to prevent coronavirus exposures by testing. The Watmind USA analyzers using the 4th Generation Microfluidic Reagent Chips provide a valuable new perspective by detecting the coronavirus antigen in the blood (N antigenemia) and can also semi-quantitate the levels of IgM, IgG, and Total Antibodies to the coronavirus S1 spike protein in 13-15 minutes showing vaccination or post-infectious immunity status. Recent emerging peer reviewed data is showing the unexpected value of antigenemia testing in SARS-CoV-2 infections typically considered a respiratory niche virus. This represents a new paradigm in point of care coronavirus COVID19 testing which is complementary and synergistic with laboratory based molecular testing.
On March 16, 2020, the FDA updated its “Policy for Diagnostic Tests for Coronavirus Disease-2019″ during the Public Health Emergency. (document download)
On March 26, WatMIND USA received its submittal confirmation from the FDA. Under the announced FDA policy, upon filing its submittal, WatMIND USA was authorized to market and distribute “WatMIND USA COVID-19 IgM / IgG Rapid Test Kits” to any licensed healthcare practitioner in the United States for diagnostic use while it awaits a final decision on its FDA EUA application. While the policy does not apply to at-home testing, the policy does allow testing in laboratories or by healthcare workers at the point-of-care.
This test has not been reviewed by the FDA. Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status. Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43 or 229E.